Prolonged survival with longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma

BACKGROUND: Though lenalidomide maintenance therapy has demonstrated improved outcomes after autologous hematopoietic stem cell transplantation (auto-HCT) in patients with multiple myeloma (MM), the impact of the duration of this therapy is not clearly known. PATIENTS AND METHODS: We retrospectively...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer
Glavni autori: Mian, Idrees, Milton, Denái R., Shah, Nina, Nieto, Yago, Popat, Uday R., Kebriaei, Partow, Parmar, Simrit, Oran, Betul, Shah, Jatin J., Manasanch, Elisabet E., Orlowski, Robert Z., Shpall, Elizabeth J., Champlin, Richard E., Qazilbash, Muzaffar H., Bashir, Qaiser
Format: Artigo
Jezik:Inglês
Izdano: 2016
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5138119/
https://ncbi.nlm.nih.gov/pubmed/27680710
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30366
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items